Susan Desmond-Hellmann's was previously Chancellor of the University of California, San Francisco, the first woman to hold the position, and Arthur and Toni Rembe Rock Distinguished Professor, and before that president of product development at Genentech, where she played a role in the development of the first gene-targeted cancer drugs, Avastin and Herceptin.
| FactSnippet No. 834,501 |
Susan Desmond-Hellmann's is board-certified in internal medicine and medical oncology, and holds a master's degree in public health from the University of California, Berkeley School of Public Health.
| FactSnippet No. 834,503 |
Susan Desmond-Hellmann served as an associate adjunct professor of epidemiology and biostatistics At UCSF.
| FactSnippet No. 834,504 |
Susan Desmond-Hellmann's was named chief medical officer the following year, and in 1999 became executive vice president of development and product operations.
| FactSnippet No. 834,505 |
Susan Desmond-Hellmann's left after the company was acquired by Roche Pharmaceuticals.
| FactSnippet No. 834,506 |
From 2005 to 2008, Susan Desmond-Hellmann served a three-year term as a member of the American Association for Cancer Research board of directors, and from 2001 to 2009, she served on the executive committee of the board of directors of the Biotechnology Industry Organization.
| FactSnippet No. 834,507 |
Susan Desmond-Hellmann's served a three-year term on the Economic Advisory Council of the Federal Reserve Bank of San Francisco beginning in January 2009.
| FactSnippet No. 834,508 |
Susan Desmond-Hellmann's said that many of her holdings had been purchased on her behalf by her stockbroker and that she was too busy to oversee all her investments, although she had included the stock on her financial disclosure statement.
| FactSnippet No. 834,509 |
In January 2012 Susan Desmond-Hellmann proposed changing the relationship between UCSF, a health sciences university, and the University of California.
| FactSnippet No. 834,510 |
Susan Desmond-Hellmann's proposed creating partnerships between UCSF and private pharmaceutical corporations and other sources of funding, in order to increase its revenues and resolve its projected financial instability.
| FactSnippet No. 834,511 |
Susan Desmond-Hellmann served as UCSF Chancellor until March 2014, holding the Arthur and Toni Rembe Rock Distinguished Professorship during her tenure.
| FactSnippet No. 834,512 |
In 2011, Susan Desmond-Hellmann co-chaired a National Academy of Sciences committee that recommended creating a Google Maps-like data network aimed at developing more diagnostics and treatments tailored to individual patients — a concept known as precision medicine.
| FactSnippet No. 834,513 |
In 2017 Susan Desmond-Hellmann became a member of the Prix Galien USA Committee, succeeding Roy Vagelos as Chair of that Committee in 2018.
| FactSnippet No. 834,514 |
Susan Desmond-Hellmann's is Chair of the Prix Galien International and Member of the Prix Galien Africa Committee.
| FactSnippet No. 834,515 |
In December 2019, Susan Desmond-Hellmann announced plans to step down from her role as BMGF CEO "for health and family reasons".
| FactSnippet No. 834,516 |
In 2021, Susan Desmond-Hellmann was appointed by President Joe Biden to the President's Council of Advisors on Science and Technology, co-chaired by Frances Arnold, Eric Lander and Maria Zuber.
| FactSnippet No. 834,517 |